Shares of Harrow (NASDAQ:HROW) plunged 20% in post-market trading Wednesday after the eye care drugmaker’s Q3 earnings report missed Street estimates on the top and bottom lines. After market close, ...
Harrow's Q2 results were solid, but meeting ambitious full-year revenue guidance will require flawless execution amid recent topline misses and a challenging market. VEVYE, IHEEZO, and TRIESENCE are ...
HC Wainwright reaffirmed their buy rating on shares of Harrow (NASDAQ:HROW – Free Report) in a research note released on Monday morning,Benzinga reports. The firm currently has a $57.00 price target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results